Delivering on FY guidance, Q4 EBITA +21% y-o-y and +15% vs cons North America & RoW better, Europe w...
We cut '23e-'25e adj. EBITDA by 15-2% Public sector weakness a drag on performance '24e EV/EBITA 4x ...
Apart from a write down of capitalized development related to the suspended projects NEX-18 and NEX-...
Redeye comments on Better Collective’s Q4-results which were in line with the preliminary outcome an...
Egetis’ Q4 report presented SEK32.6m in revenues, of which SEK14.
Redeye updates its estimates following Surgical Science’s Q4 2023 report, which featured an unusuall...
EBITDA and FCF surprised positively in Q4 Much better profitability in '24e-'26e offsets weaker grow...
Redeye in this note comments on today's year-end report, but especially the recent news flow in Jond...
Sales SEK 7.6m (12.2m), adj. EBIT SEK -18.0m (-8.6m) Several strategic agreements signed, investing ...
Stabil verksamhet men fortsatta utmaningar med finansieringen Gigasun rapporterade operationellt en ...
Syncro Group har publicerat bolagets delårsrapport för det fjärde kvartalet 2023.
Svaghet med ljus i tunneln Efter flera svaga kvartal och tuffa marknadsförhållanden hade vi lågt stä...
CAG uppvisar betydligt mer stabilitet än sina branschkollegor Generellt har 2023 varit ett utmanande...
Låg försäljning i Q4 Fjolåret avslutades svagare än vad vi hade räknat med och nettoomsättningen min...
Redeye saw a Q4 report showing sales below our estimates, with a total growth of 16% for the quarter...
NEX-22 start potentially delayed into Q2'24e (Q1'24e) Next milestone: NEX-22 Ph 1 approval Webcast t...
Redeye comments on Raketech’s Q4-results which were in line with our forecasts.
Redeye in this note provides a quick first comment on the Smart Eye year-end report.
Net sales SEK 190m, -3% vs ABGSCe, +3% vs Factset cons.
Redeye missed on sales and EBIT but was positively surprised by the strong gross margin.
.jpg)
